SCHEMBL3490433

SCHEMBL3490433

Fc1cccc(CCc2nnc(-c3ccnc4[nH]ccc34)o2)c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDC7 O00311 3/20 0.51
CDK2 P24941 3/20 0.51
CCNE1 P24864 2/20 0.51
DBF4 Q9UBU7 2/20 0.51
ROCK1 Q13464 3/20 0.46
ROCK2 O75116 2/20 0.46
GSK3B P49841 3/20 0.45
PIM1 P11309 2/20 0.42
EGFR P00533 1/20 0.42
PRKCA P17252 1/20 0.42
AKT1 P31749 1/20 0.42
AKT2 P31751 1/20 0.42
SYK P43405 1/20 0.42
MAPKAPK2 P49137 1/20 0.42
MAPK14 Q16539 1/20 0.42
AKT3 Q9Y243 1/20 0.42
NUDT1 P36639 4/20 0.40
NR3C2 P08235 1/20 0.40
CCNK O75909 2/20 0.40
CDK12 Q9NYV4 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3491981 0.87 ROCK2 (0.48) CDC7CDK2CCNE1DBF4ROCK1
SCHEMBL3491934 0.81 GSK3B (0.58) CDC7CDK2CCNE1DBF4ROCK1
SCHEMBL2358127 0.80 MAP4K4 (0.51) CDC7CDK2CCNE1DBF4ROCK1
SCHEMBL2355622 0.78 AURKB (0.52) CDC7CDK2CCNE1DBF4ROCK1
SCHEMBL5112553 0.75 IKBKB (0.47) CDK2ROCK1NUDT1CCNKCDK12
SCHEMBL2356243 0.75 CIT (0.47) ROCK1NUDT1CCNKCDK12DYRK1A
SCHEMBL2356502 0.75 ROCK1 (0.48) CDC7CDK2CCNE1DBF4ROCK1
SCHEMBL2357112 0.73 NUDT1 (0.51) CDC7CDK2CCNE1DBF4ROCK1
Cyclopentane SCHEMBL2358084 0.72 CCNK (0.48) ROCK1NUDT1CCNKCDK12DYRK1A
SCHEMBL2358817 0.72 JAK2 (0.46) CDK2ROCK1ROCK2GSK3BPRKCA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8492378-B2 GSK-3β inhibitor TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-07-23 US disclosed
US-20100069381-A1 GSK-3BETAINHIBITOR TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-03-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100069381-A1 GSK-3BETAINHIBITOR GSK3B, GSK3A, GSKIP CDC7 1097/4885CDK2 323/4885CCNE1 2505/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.